PaxVax Corporation

Kinnate Biopharma Inc. CEO Nima Farzan notes that while about 10% of cancer patients are eligible for treatment with a targeted oncology drug only half respond to treatment and about half of the resp

The US Food and Drug Administration’s efforts to build a framework for speeding responses to emerging infectious diseases and biowarfare threats – collectively known as medical countermeasures – have

Themis Bioscience GmbH will lay out plans for pre- and post-licensure studies to support approval MV-CHIK, one of the first chikungunya virus vaccines to approach pivotal clinical trials, as part of

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in